{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:24:56Z","timestamp":1780410296785,"version":"3.54.1"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T00:00:00Z","timestamp":1536537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Melinta Therapeutics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Fluoroquinolones have been widely used for a variety of Gram-positive and Gram-negative infections, and by 2002 they had become the most commonly prescribed class of antibiotics for adults in the United States. With widespread use, the class has become associated with a range of adverse events. Delafloxacin is a fluoroquinolone approved in the United States for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSIs). Delafloxacin is differentiated from other fluoroquinolones due to structural differences and in its activity against methicillin-resistant Staphylococcus aureus, including quinolone-resistant strains. This paper reviews the safety profile of delafloxacin across clinical studies with an emphasis on the incidence of adverse events of special interest that are associated with fluoroquinolones.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from 2 completed phase III studies of delafloxacin for the treatment of ABSSSIs were pooled and are the primary focus of this paper. Additional support from the full safety analysis set (30 completed phase I to phase III clinical studies) is included where applicable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fewer patients in the pooled delafloxacin group had AESIs than in the comparator group (7.0% vs 9.2%, respectively). Delafloxacin had a low rate of discontinuations due to treatment-related adverse events (&amp;lt;1%). Serious adverse events occurred at similar rates in patients treated with delafloxacin vs comparators.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Serious adverse events occurred at similar rates in patients treated with delafloxacin vs nonquinolone comparators used to treat ABSSSIs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinicaltrials.gov identifier<\/jats:title><jats:p>NCT01984684 and NCT01811732<\/jats:p><\/jats:sec>","DOI":"10.1093\/ofid\/ofy220","type":"journal-article","created":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T05:03:11Z","timestamp":1536555791000},"source":"Crossref","is-referenced-by-count":28,"title":["Safety of Delafloxacin: Focus on Adverse Events of Special Interest"],"prefix":"10.1093","volume":"5","author":[{"given":"Thomas","family":"Lodise","sequence":"first","affiliation":[{"name":"Albany College of Pharmacy and Health Sciences, Albany, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Corey","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hooper","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3796-807X","authenticated-orcid":false,"given":"Sue","family":"Cammarata","sequence":"additional","affiliation":[{"name":"Melinta Therapeutics, Lincolnshire, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,9,10]]},"reference":[{"key":"2020081004073568400_CIT0001","volume-title":"FDA briefing document. Joint meeting of the Antimicrobial Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee","author":"US Food and Drug Administration","year":"2015"},{"key":"2020081004073568400_CIT0002","volume-title":"FDA drug safety communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects","author":"US Food and Drug Administration","year":"2016"},{"key":"2020081004073568400_CIT0003","volume-title":"FDA drug safety communication: FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes","author":"US Food and Drug Administration","year":"2018"},{"key":"2020081004073568400_CIT0004","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40121-018-0198-x","article-title":"Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties","volume":"7","author":"Jorgensen","year":"2018","journal-title":"Infect Dis Ther"},{"key":"2020081004073568400_CIT0005","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2217\/fmb.15.39","article-title":"Delafloxacin, a non-zwitterionic fluoroquinolone in phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy","volume":"10","author":"Van Bambeke","year":"2015","journal-title":"Future Microbiol"},{"key":"2020081004073568400_CIT0006","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.01201-10","article-title":"Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus","volume":"55","author":"Lemaire","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004073568400_CIT0007","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1093\/jac\/dkx329","article-title":"Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a phase 3, double-blind, randomized study","volume":"72","author":"Pullman","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020081004073568400_CIT0008","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/cid\/ciy165","article-title":"A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study","volume":"67","author":"O\u2019Riordan","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020081004073568400_CIT0009","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12941-016-0150-4","article-title":"Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin","volume":"15","author":"Kocsis","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2020081004073568400_CIT0010","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/jac\/dkv411","article-title":"A randomized, double-blind, phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin","volume":"71","author":"Kingsley","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020081004073568400_CIT0011","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijid.2014.10.009","article-title":"A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections","volume":"30","author":"O\u2019Riordan","year":"2015","journal-title":"Int J Infect Dis"},{"key":"2020081004073568400_CIT0012","volume-title":"A phase 2 study of the safety and efficacy of oral delafloxacin (DLX) in community acquired pneumonia (CAP) [Poster 1069]","author":"Longcor"},{"key":"2020081004073568400_CIT0013","volume-title":"A phase 2 study of the safety and efficacy of oral delafloxacin (DLX) in subjects with acute bacterial exacerbation of chronic bronchitis (ABECB) [Poster 1071]","author":"Longcor"},{"key":"2020081004073568400_CIT0014","volume-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Understanding MedDRA: The Medical Dictionary for Regulatory Activities","year":"2013"},{"key":"2020081004073568400_CIT0015","volume-title":"Comparison of delafloxacin (DLX) and vancomycin (VAN) in the treatment of acute bacterial skin and skin structure infections (ABSSSI) by age and gender in two phase 3 trials [Poster 1153]","author":"Hansen"},{"key":"2020081004073568400_CIT0016","volume-title":"Delafloxacin (DLX) is effective and well-tolerated in treatment of diabetic (DM) patients with acute bacterial skin and s AQ10 kin structure infections (ABSSSI) versus vancomycin\/aztreonam (VAN\/AZ) [Poster P1353]","author":"Giordano"},{"key":"2020081004073568400_CIT0017","volume-title":"Delafloxacin (DLX) is effective and well-tolerated in treatment of obese patients with acute bacterial skin and skin structure infections (ABSSSI) versus vancomycin\/ aztreonam (VAN\/AZ) [Poster 1354]","author":"Shah"},{"key":"2020081004073568400_CIT0018","volume-title":"Delafloxacin (DLX is effective and well-tolerated in treatment of patients with renal impairment with acute bacterial skin and skin structure infections (AGBSSSI) versus vancomycin\/aztreonam (VAN\/AZ). Poster P1355. Poster presented at: ECCMID 2017","author":"Beasley"},{"key":"2020081004073568400_CIT0019","volume-title":"Delafloxacin (DLX) is effective and well-tolerated compared to vancomycin\/aztreonam (VAN\/AZ) in treatment of paitnes with acute bacterial skin and skin structure infections (ABSSSI) and history of infectious hepatitis. Poster 235. Paper presented at: ASM Microbe 2017; June 1\u20135, 2017","author":"Tien"},{"key":"2020081004073568400_CIT0020","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1039\/C8PP00019K","article-title":"Lack of phototoxicity potential with delafloxacin in healthy male and female subjects: comparison to lomefloxacin","volume":"17","author":"Dawe","year":"2018","journal-title":"Photochem Photobiol Sci"},{"key":"2020081004073568400_CIT0021","volume-title":"Summary basis of approval \u2013 Baxdela\u2122 (delafloxacin) application number 208610Orig1s000","author":"FDA","year":"2017"},{"key":"2020081004073568400_CIT0022","volume-title":"FDA briefing document: joint meeting of the Antimicrobial Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, November 5, 2015","author":"Food and Drug Administration","year":"2015"},{"key":"2020081004073568400_CIT0023","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.amjmed.2004.09.015","article-title":"Fluoroquinolone prescribing in the United States: 1995 to 2002","volume":"118","author":"Linder","year":"2005","journal-title":"Am J Med"},{"key":"2020081004073568400_CIT0024","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1471-2334-11-187","article-title":"Unnecessary use of fluoroquinolone antibiotics in hospitalized patients","volume":"11","author":"Werner","year":"2011","journal-title":"BMC Infect Dis"},{"key":"2020081004073568400_CIT0025","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1310\/hpj4511-844","article-title":"Strategies to address appropriate fluoroquinolone use in the hospital","volume":"45","author":"Kaye","year":"2010","journal-title":"Hosp Pharm"},{"key":"2020081004073568400_CIT0026","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/jac\/33.4.685","article-title":"Structure-activity and structure-side-effect relationships for the quinolone antibacterials","volume":"33","author":"Domagala","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"2020081004073568400_CIT0027","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1128\/AAC.48.3.799-803.2004","article-title":"New findings on the structure-phototoxicity relationship and photostability of fluoroquinolones with various substituents at position 1","volume":"48","author":"Hayashi","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004073568400_CIT0028","doi-asserted-by":"crossref","first-page":"2324709614545225","DOI":"10.1177\/2324709614545225","article-title":"Permanent peripheral neuropathy: a case report on a rare but serious debilitating side-effect of fluoroquinolone administration","volume":"2","author":"Francis","year":"2014","journal-title":"J Investig Med High Impact Case Rep"},{"key":"2020081004073568400_CIT0029","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1600-0773.1989.tb00676.x","article-title":"Neurochemical studies on quinolone antibiotics: effects on glutamate, GABA and adenosine systems in mammalian CNS","volume":"64","author":"Dodd","year":"1989","journal-title":"Pharmacol Toxicol"},{"key":"2020081004073568400_CIT0030","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2174\/0929867013373435","article-title":"Adverse reactions to fluoroquinolones. An overview on mechanistic aspects","volume":"8","author":"De Sarro","year":"2001","journal-title":"Curr Med Chem"},{"key":"2020081004073568400_CIT0031","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/1574886308666140106154754","article-title":"Third and fourth generation fluoroquinolone antibacterials: a systematic review of safety and toxicity profiles","volume":"9","author":"Sousa","year":"2014","journal-title":"Curr Drug Saf"},{"key":"2020081004073568400_CIT0032","volume-title":"Ciprofloxacin. LiverTox: clinical and research information on drug-induced liver injury","author":"US National Library of Medicine, National Institutes of Health","year":"2017"},{"key":"2020081004073568400_CIT0033","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00002018-200932050-00001","article-title":"Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes","volume":"32","author":"Van Bambeke","year":"2009","journal-title":"Drug Saf"},{"key":"2020081004073568400_CIT0034","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cgh.2011.02.019","article-title":"Clinical and histopathologic features of fluoroquinolone-induced liver injury","volume":"9","author":"Orman","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020081004073568400_CIT0035","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/600294","article-title":"Severe dysglycemia with the fluoroquinolones: a class effect","volume":"49","author":"Aspinall","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020081004073568400_CIT0036","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/cid\/cit439","article-title":"Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan","volume":"57","author":"Chou","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020081004073568400_CIT0037","first-page":"639","article-title":"Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia","volume":"11","author":"Kabbara","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"2020081004073568400_CIT0038","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1592\/phco.28.1.82","article-title":"Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting","volume":"28","author":"LaPlante","year":"2008","journal-title":"Pharmacotherapy"},{"key":"2020081004073568400_CIT0039","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1592\/phco.2005.25.10.1303","article-title":"A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone","volume":"25","author":"Mohr","year":"2005","journal-title":"Pharmacotherapy"},{"key":"2020081004073568400_CIT0040","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1056\/NEJMoa055191","article-title":"Outpatient gatifloxacin therapy and dysglycemia in older adults","volume":"354","author":"Park-Wyllie","year":"2006","journal-title":"N Engl J Med"},{"key":"2020081004073568400_CIT0041","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1128\/AAC.04813-14","article-title":"A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization","volume":"59","author":"Litwin","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004073568400_CIT0042","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1086\/508873","article-title":"Antimicrobial-associated QT interval prolongation: pointes of interest","volume":"43","author":"Owens","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2020081004073568400_CIT0043","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1124\/mol.59.1.122","article-title":"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG","volume":"59","author":"Kang","year":"2001","journal-title":"Mol Pharmacol"},{"key":"2020081004073568400_CIT0044","article-title":"Safety Pharmacology Studies Assessing the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals"},{"key":"2020081004073568400_CIT0045","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/030098589002700303","article-title":"Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone","volume":"27","author":"Burkhardt","year":"1990","journal-title":"Vet Pathol"},{"key":"2020081004073568400_CIT0046","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/jor.22094","article-title":"Glutamate receptors in tendinopathic patients","volume":"30","author":"Schizas","year":"2012","journal-title":"J Orthop Res"},{"key":"2020081004073568400_CIT0047","doi-asserted-by":"crossref","first-page":"1228.e23","DOI":"10.1016\/j.amjmed.2012.05.027","article-title":"Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders","volume":"125","author":"Wise","year":"2012","journal-title":"Am J Med"},{"key":"2020081004073568400_CIT0048","first-page":"461","article-title":"Fluoroquinolone-associated tendinopathy","volume":"34","author":"Tsai","year":"2011","journal-title":"Chang Gung Med J"},{"key":"2020081004073568400_CIT0049","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/phar.1761","article-title":"Fluoroquinolone-associated tendinopathy: does levofloxacin pose the greatest risk","volume":"36","author":"Bidell","year":"2016","journal-title":"Pharmacotherapy"},{"key":"2020081004073568400_CIT0050","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1155\/2002\/864789","article-title":"Safety of fluoroquinolones: an update","volume":"13","author":"Mandell","year":"2002","journal-title":"Can J Infect Dis"},{"key":"2020081004073568400_CIT0051","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1503\/cmaj.121270","article-title":"Liver injury in the elderly due to fluoroquinolones: should these drugs be avoided","volume":"184","author":"Hayashi","year":"2012","journal-title":"CMAJ"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/5\/10\/ofy220\/33576334\/ofy220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/5\/10\/ofy220\/33576334\/ofy220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T01:02:47Z","timestamp":1751850167000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofy220\/5093787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,10]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofy220","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,10]]},"published":{"date-parts":[[2018,9,10]]},"article-number":"ofy220"}}